Characteristics and Safety Profile in Patient Received Ixazomib in China: Interim Analysis of a National, Prospective, Non-Interventional Study of Using Ixazomib in Real-World Clinical Practice (INFINITE Study)

伊扎莫布 临时的 中期分析 医学 临床实习 临床试验 家庭医学 医学物理学 重症监护医学 内科学 历史 多发性骨髓瘤 Carfilzomib公司 蛋白酶体抑制剂 考古
作者
Chengcheng Fu,Xin Zhou,Junling Zhuang,Fan Zhou,Yuhua Li,Wen-Ming Chen,Rong Fu,Baijun Fang,Ting Niu,Hao Zhang,Lin Li,Depei Wu
出处
期刊:Blood [American Society of Hematology]
卷期号:140 (Supplement 1): 12642-12644
标识
DOI:10.1182/blood-2022-165127
摘要

Background: China Food and Drug Administration formally approved the marketing of imported Ixazomib Citrate capsules in China on Apr 25, 2018. Pre-marketing clinical research was conducted restrictively in relapsed refractory multiple myeloma (RRMM) patients (pts) with multiple exclusion criteria and was not a comprehensive reflection of Ixazomib (IXA) real-world pts safety circumstances. Therefore, it is necessary to conduct a prospective post-marketing study to understand the gap between real clinical practice and pre-marketing clinical research. Aim: To report the characteristics and safety profile of IXA in Chinese multiple myeloma pts. We report an interim analysis (IA) of the INFINITE study. Method: INFINITE Study (NCT04328662) is a prospective, non-interventional, single-country study. Pts who have received at least one dose of IXA-based regimen treatment, with IXA < 3 months from their initial treatment or will be prescribed were included in the study. The enrolled pts with RRMM who received at least one dose of IXA-lenalidomide-dexamethasone (IRd) treatment were assigned to cohort 1. The newly diagnosed multiple myeloma (NDMM) and non-myeloma pts who have received at least one dose of IXA-based regimen, and RRMM pts who have received at least one dose of non-IRd IXA-based treatment were assigned to cohort 2. The primary outcome of this analysis is to evaluate the safety profile of IXA in a Chinese patient population. The secondary outcomes are effectiveness (ORR, DOT, TTNT, PFS, OS) of IXA in RRMM patients, safety, and efficacy based on clinical / disease characteristics as defined in cohort 1 and cohort 2. The time to event outcomes was estimated by the Kaplan-Meier method for incomplete observations and all statistical analysis were performed using SAS Enterprise Guide 8.3 software. Results: As of 31 Jan 2022 (data cut-off), 114 pts (Cohort 1 (n=6); Cohort 2 (n=108)) were enrolled and considered for data analysis. Among these, 10 pts had discontinued/withdrew from the study (1 pts due to disease progression, 2 pts due to death, 7 pts for other reasons). On overall evaluation at baseline 114 pts have been treated with IXA; median age 65 yrs [range 34-89]; 59.6% male; 35.1% with ISS III disease; 26.3% with R-ISS III disease; 62.3% with Durie-Salmon stage III; 32.5% with high-risk by Stratification of Mayo mSMART guidelines; 15.8% patient received stem cell transplantation. 78.9/17.5/7.0/ 2.6% pts had received prior treatment in L1/L2/L3/other respectively, before IXA. Further, 64 %pts received a V-based regimen including VCD/VRD/VTD in first-line therapy. Route of bortezomib administration was by intravenous injection and subcutaneous injection in 21.9% and 48.2% pts respectively, with the rest unknown. At baseline evaluation, 2.6/7.9/8.8/4.4% pts had achieved sCR/CR/VGPR/PR (Table 1). At the time of this IA, median follow-up is 4.01 month, 91.2% (104/114) of pts were still on therapy and enrollment is ongoing. Median duration from the start of IXA-based treatment was 3.5 months. The median time to next treatment was 3.8 months. Treatment-emergent adverse events (TEAEs) related to IXA were 43.0% and treatment-emergent serious adverse events (SAE) related to IXA were 4.4%. TEAEs leading to treatment discontinuation (temporary and permanent) were 7.9%. TEAEs leading to discontinuation of the study were 0.9%. SAEs leading to treatment discontinuation (temporary and permanent) were 2.6%. SAEs leading to discontinuation of the study were 0.9%. TEAE of special interest were 4.4%. TEAE with Outcome of Death is 1.8% (Table 2). Conclusion: The interim analysis results show characteristics in pts receiving IXA in real-world clinical practice. The safety profile of IXA in Chinese patients is consistent with the TOURMALINE-MM1-China Continuation Study. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
千幻完成签到,获得积分10
2秒前
3秒前
5秒前
领导范儿应助Shaw采纳,获得10
7秒前
康康发布了新的文献求助10
8秒前
克洛里完成签到,获得积分10
10秒前
内向友桃完成签到 ,获得积分10
12秒前
呱呱发布了新的文献求助10
12秒前
小马哥完成签到,获得积分10
13秒前
13秒前
NNNN完成签到,获得积分20
16秒前
17秒前
17秒前
18秒前
Shaw发布了新的文献求助10
19秒前
21秒前
遇鲸还潮完成签到,获得积分10
21秒前
22秒前
英姑应助LD采纳,获得10
23秒前
呱呱完成签到,获得积分10
25秒前
25秒前
有且仅有发布了新的文献求助10
27秒前
传奇3应助杰克李李采纳,获得10
28秒前
思无邪完成签到 ,获得积分10
29秒前
活力书包完成签到 ,获得积分10
32秒前
李渤海发布了新的文献求助20
33秒前
35秒前
ddak发布了新的文献求助10
35秒前
Ava应助nini采纳,获得10
37秒前
37秒前
科研通AI2S应助苗儿采纳,获得10
37秒前
39秒前
康康完成签到 ,获得积分10
40秒前
YHYHYH发布了新的文献求助10
41秒前
42秒前
42秒前
xzw完成签到,获得积分10
44秒前
www完成签到 ,获得积分10
45秒前
潘杨霞发布了新的文献求助20
46秒前
曾经晓亦完成签到 ,获得积分20
47秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Foreign Policy of the French Second Empire: A Bibliography 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
XAFS for Everyone 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3143731
求助须知:如何正确求助?哪些是违规求助? 2795219
关于积分的说明 7813671
捐赠科研通 2451210
什么是DOI,文献DOI怎么找? 1304353
科研通“疑难数据库(出版商)”最低求助积分说明 627221
版权声明 601400